期刊文献+

二次检索

题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到6篇文章
< 1 >
每页显示 20 50 100
中国创新生物药的研究进展 被引量:3
1
作者 王春明 夏智星 +4 位作者 郭银银 周峰 易博 李佳 俞德超 《中国新药杂志》 CAS CSCD 北大核心 2014年第20期2406-2410,共5页
创新生物药是未来新药研发的主要方向,是中国从医药大国迈向医药强国的重要突破口。本文概述了国内已批准上市和进入临床研究的、具有自主知识产权的一类创新生物药的研究进展,重点介绍了具有里程碑意义的4个自主创新生物药,分别为肿瘤... 创新生物药是未来新药研发的主要方向,是中国从医药大国迈向医药强国的重要突破口。本文概述了国内已批准上市和进入临床研究的、具有自主知识产权的一类创新生物药的研究进展,重点介绍了具有里程碑意义的4个自主创新生物药,分别为肿瘤免疫基因治疗类药物"今又生"和"安柯瑞"以及单克隆抗体类药物"利卡汀"和融合蛋白类药物"朗沐",并在此基础上指明当前生物药创新存在的机遇和挑战,提出我们的建议。 展开更多
关键词 创新生物药 肿瘤免疫基因治疗 单克隆抗体 融合蛋白 研究进展
原文传递
生物类似药与改良创新生物药的产业态势对比分析 被引量:2
2
作者 韩佳 郑晓南 《药学进展》 CAS 2018年第6期439-449,共11页
伴随监管政策法规的日趋成熟以及各利益相关方对生物类似药与改良创新生物药的逐渐接受,对生物类似药与改良创新生物药这2类生物药的产业态势有一个清晰全面的了解,有助于生物制药企业制定合理的投资合作发展战略,从而促进其生物药研发... 伴随监管政策法规的日趋成熟以及各利益相关方对生物类似药与改良创新生物药的逐渐接受,对生物类似药与改良创新生物药这2类生物药的产业态势有一个清晰全面的了解,有助于生物制药企业制定合理的投资合作发展战略,从而促进其生物药研发和参与区域或全球市场竞争。在对生物类似药与改良创新生物药作清晰定义后,从主要国家或区域市场的研发进展、竞争格局、优劣势以及风险与价值等角度对生物类似药与改良创新生物药的产业态势进行对比分析,以期为相关机构在生物制药行业开展研发、合作、投资、市场活动的发展战略制定与实施提供基于竞争情报的决策支持。 展开更多
关键词 生物类似 改良创新生物药 研发进展 竞争格局 对比分析
原文传递
“双碳”背景下百济神州ESG信息披露实践与启示
3
作者 赵希桐 任嘉 《世界经济探索》 2024年第3期367-372,共6页
2024年4月12日,沪深北三大交易所正式发布了《上市公司可持续发展报告指引》(以下简称《指引》),并自2024年5月1日起实施。绿色环保和降低碳排放一直是全球人士关注的问题,在此背景下,习主席提出了努力将二氧化碳排放在2030年达到峰值,2... 2024年4月12日,沪深北三大交易所正式发布了《上市公司可持续发展报告指引》(以下简称《指引》),并自2024年5月1日起实施。绿色环保和降低碳排放一直是全球人士关注的问题,在此背景下,习主席提出了努力将二氧化碳排放在2030年达到峰值,2060年达到中和的“双碳”目标。ESG与全球生态息息相关,也是推动经济高质量发展的重要工具,可以为中国实现“双碳”做出贡献。目前患肿瘤等疾病的人数不断攀升,肿瘤药物的创新研发具有重大意义,但同时制药又是重污染来源,亟需完善ESG治理。百济神州在生物创新药行业有一定的代表意义,本文以百济神州为例,研究其ESG信息披露的实践与可改进部分,从而给生物创新药行业带来借鉴意义。On April 12, 2024, the three major stock exchanges in Shanghai, Shenzhen and North China officially issued the Guidelines for Sustainability Reporting of Listed Companies (hereinafter referred to as the “Guidelines”), which will be implemented from May 1, 2024. In this context, President Xi Jinping has proposed to strive to peak carbon dioxide emissions by 2030 and achieve neutrality by 2060. ESG is closely related to the global ecology and is also an important tool to promote high-quality economic development, which can contribute to China’s “dual carbon” efforts. At present, the number of people suffering from tumors and other diseases is rising, and the innovative research and development of oncology drugs is of great significance, but at the same time, pharmaceuticals are a source of heavy pollution, and ESG governance needs to be improved urgently. BeiGene has a certain representative significance in the bio-innovative drug industry, and this article takes BeiGene as an example to study the practice and improvement of its ESG information disclosure, so as to bring reference significance to the bio-innovative drug industry. 展开更多
关键词 “双碳” ESG 百济神州 生物创新行业
下载PDF
Innovative therapeutics for inflammatory bowel disease 被引量:10
4
作者 Jesus K Yamamoto-Furusho 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第13期1893-1896,共4页
Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, Crohn's disease or ulcerative colitis. Mainstays of drug treat... Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, Crohn's disease or ulcerative colitis. Mainstays of drug treatments for IBD include aminosalicylates, corticosteroids and immunosuppressants such as azathioprine, methotrexate and cyclosporin. Advances in basic research of the pathophysiological process in IBD have been applied to generate a variety of new therapeutics targeting at different levels of the inflammatory processes. New therapies are classified as: (1) Anti-TNFα antibodies; (2) Recombinant cytokines; (3) Selective adhesion blockade; (4) Growth factors; (5) Innate immunostimulation; (6) Nucleic acid based therapies; (7) Gene therapy; (8) Autologous bone-marrow transplantation; (9) Helminths and (10) Extracorporeal immunomodulation. All treatments have the potential to provide more effective and safe treatment for IBD. 展开更多
关键词 Novel agents Inflammatory bowel diseases Biologic therapy Future agents
下载PDF
Erythropoietin: From a Biosimilar to Innovative Products Protected by Industrial Property Assets
5
作者 Lien Lopez Matilla Pedro Barzaga Fernandezt Sonia Gonzalez Blanco 《Journal of Pharmacy and Pharmacology》 2017年第9期681-687,共7页
Aim: EPO (erythropoietin) is a hormone that stimulates the erythropoiesis and is mainly produced by the kidneys. In the early 1990s among the emerging biotech drugs, the recombinant human EPO (rhEPO) was the best... Aim: EPO (erythropoietin) is a hormone that stimulates the erythropoiesis and is mainly produced by the kidneys. In the early 1990s among the emerging biotech drugs, the recombinant human EPO (rhEPO) was the best-selling product worldwide, reaching nearly three billion dollars annually. The CIM (center of molecular immunology) produced and sold the rhEPO as commercial strategy to recover the investment made in its new facilities. This work summarizes the inventions that protect the innovative products developed by three Cuban institutions, starting from rhEPO, and the industrial property strategy followed by them. Methods: The information was obtained from the United States Patent, Trademark Office (USPTO) database, Patentscope, Espacenet, patent databases of Center for Pharmaceutical Research and Drug Development (CIDEM) and Cuban Industrial Property Office. Conclusions: The manufacturing process of CIM's EPO has its own patent family. From a manufacturing by product an innovative formulation protected by patent was obtained. There is a patent family around the nasal formulation and it continues enlarging. From a biosimilar pharmaceutical innovative products impacting on human health have been obtained. 展开更多
关键词 ERYTHROPOIETIN ATAXIA pegylated EPO biosimilar.
下载PDF
Chemomics and drug innovation 被引量:1
6
作者 XU Jun GU Qiong +8 位作者 LIU HaiBo ZHOU JiaJu BU XianZhang HUANG ZhiShu LU Gui LI Ding WEI DongQing WANG Ling GU LianQuan 《Science China Chemistry》 SCIE EI CAS 2013年第1期71-85,共15页
Chemomics is an interdisciplinary study using approaches from chemoinformatics,bioinformatics,synthetic chemistry,and other related disciplines.Biological systems make natural products from endogenous small molecules ... Chemomics is an interdisciplinary study using approaches from chemoinformatics,bioinformatics,synthetic chemistry,and other related disciplines.Biological systems make natural products from endogenous small molecules (natural product building blocks) through a sequence of enzyme catalytic reactions.For each reaction,the natural product building blocks may contribute a group of atoms to the target natural product.We describe this group of atoms as a chemoyl.A chemome is the complete set of chemoyls in an organism.Chemomics studies chemomes and the principles of natural product syntheses and evolutions.Driven by survival and reproductive demands,biological systems have developed effective protocols to synthesize natural products in order to respond to environmental changes;this results in biological and chemical diversity.In recent years,it has been realized that one of the bottlenecks in drug discovery is the lack of chemical resources for drug screening.Chemomics may solve this problem by revealing the rules governing the creation of chemical diversity in biological systems,and by developing biomimetic synthesis approaches to make quasi natural product libraries for drug screening.This treatise introduces chemomics and outlines its contents and potential applications in the fields of drug innovation. 展开更多
关键词 chemomics CHEMOINFORMATICS BIOINFORMATICS drug innovation biomimetic synthesis
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部